Nitric oxide synthase (NOS) (NOS)

Nitric oxide synthase (NOS) is a family of enzymes that catalyze the synthesis of nitric oxide (NO) from L-arginine, a process essential for various physiological signaling pathways [1.3.3]. The family includes three main isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS), which are distributed across different tissues and serve specialized functions [1.3.2]. eNOS primarily regulates vascular tone and blood pressure, nNOS facilitates neurotransmission and muscle relaxation, and iNOS mediates immune responses and inflammation [1.1.1, 1.3.5]. Pathological dysregulation of these isoforms is implicated in a wide range of diseases, such as hypertension, atherosclerosis, septic shock, and neurodegenerative conditions like Alzheimer's disease [1.3.1, 1.4.1]. Therapeutic strategies target NOS through isoform-selective inhibitors to reduce excessive NO production in inflammatory or neurotoxic states, or through enhancers to restore NO bioavailability in cardiovascular disease [1.2.3, 1.4.2]. A significant challenge in targeting NOS is achieving high selectivity to prevent off-target effects, such as the systemic hypotension that can result from unintended eNOS inhibition [1.1.2, 1.2.1]. Additionally, "NOS uncoupling" under oxidative stress can lead the enzyme to produce harmful superoxide instead of NO, further complicating therapeutic interventions [1.1.2, 1.3.2]. Clinical candidates like Ronopterin (VAS203) and Tilarginine (L-NMMA) have been investigated for conditions such as traumatic brain injury and cardiogenic shock, respectively [1.2.3, 1.2.4].

Other names

Nitric oxide synthasesnNOSiNOSeNOSNOS1NOS2NOS3Nitric-oxide synthase (NADPH)Peptidyl-L-arginine oxidoreductase

Competitive inhibition of the L-arginine binding site, inhibition of enzyme dimerization, competition with the tetrahydrobiopterin (BH4) cofactor, and restoration of enzyme coupling to increase nitric oxide bioavailability.